Holen Sie sich die Stockscreener-App
47.71
1.47%
0.69
Handel nachbörslich:
47.71
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Apogee Therapeutics (NASDAQ:APGE) Stock Price Down 3.2%Here's Why - MarketBeat
Trend Tracker for (APGE) - Stock Traders Daily
Franklin Resources Inc. Has $48.05 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Trading Up 6.1% After Insider Buying Activity - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Price Target at $83.88 - Defense World
Apogee Therapeutics (NASDAQ:APGE) Trading 6.1% Higher Following Insider Buying Activity - MarketBeat
State Street Corp Cuts Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up Following Insider Buying Activity - Defense World
Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up After Insider Buying Activity - MarketBeat
Insider Buying: Mark Mckenna Acquires 20,000 Shares of Apogee Th - GuruFocus.com
Apogee Therapeutics, Inc. (NASDAQ:APGE) Director Mark C. Mckenna Acquires 20,000 Shares of Stock - MarketBeat
Apogee Therapeutics : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.com
Apogee Therapeutics director Mark McKenna acquires $990,775 in stock - Investing.com
Apogee Therapeutics director Mark McKenna acquires $990,775 in stock By Investing.com - Investing.com South Africa
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.89 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Sees Large Growth in Short Interest - MarketBeat
Barclays PLC Grows Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,540 Shares - MarketBeat
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $83.88 - MarketBeat
Apogee Therapeutics' chief medical officer sells $221,362 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics' chief medical officer sells $221,362 in stock - Investing.com
Financial Survey: Apogee Therapeutics (NASDAQ:APGE) versus DBV Technologies (NASDAQ:DBVT) - Defense World
Guggenheim maintains buy on Apogee stock amid trial failures - Investing.com
Apogee Therapeutics, Inc. Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions - Marketscreener.com
Apogee Therapeutics Advances Clinical Trials for APG333 - TipRanks
Apogee Therapeutics Announces First Participants Dosed in - GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its - The Bakersfield Californian
Apogee Therapeutics Launches Phase 1 Trial for Novel Asthma Treatment, Marking 4th Clinical Program - StockTitan
Wellington Management Group LLP Buys 1,267,451 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Position Boosted by Charles Schwab Investment Management Inc. - MarketBeat
Carl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $698,700.00 in Stock - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Janus Henderson Group PLC - MarketBeat
Apogee Therapeutics CEO Michael Henderson sells shares worth $698,653 By Investing.com - Investing.com Nigeria
Apogee Therapeutics CEO Michael Henderson sells shares worth $698,653 - Investing.com
Apogee Therapeutics' chief medical officer sells shares worth $307,056 By Investing.com - Investing.com UK
Point72 Asset Management L.P. Increases Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Guggenheim Reaffirms Buy Rating for Apogee Therapeutics (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by HighVista Strategies LLC - MarketBeat
Apogee Therapeutics Advances in I&I Disease Treatments - Yahoo Finance
Apogee Therapeutics Highlights Progress and Potential in Biologic Programs at R&D Day - Defense World
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $90.00 at Wedbush - Defense World
Apogee Therapeutics Highlights Progress and Best-in-Class - GlobeNewswire
Apogee Therapeutics Highlights Progress and Best-In-Class Potential of Novel Biologic Programs for I&I Diseases At 2024 Inaugural R&D Day Include - Marketscreener.com
Apogee Therapeutics price target raised to $110 from $95 at Guggenheim - MSN
Braidwell LP Lowers Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Apogee Therapeutics Announces Agenda for Virtual R&D Day - Marketscreener.com
Apogee Therapeutics Sets R&D Day to Unveil APG808 Clinical Trial Results, Pipeline Updates | APGE Stock News - StockTitan
Vestal Point Capital LP Buys Shares of 136,500 Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Guggenheim lifts Apogee Therapeutics shares target on strategy By Investing.com - Investing.com Australia
Long Term Trading Analysis for (APGE) - Stock Traders Daily
Natixis Advisors LLC Invests $879,000 in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat
Guggenheim lifts Apogee Therapeutics shares target on strategy - Investing.com
Guggenheim Issues Positive Forecast for Apogee Therapeutics (NASDAQ:APGE) Stock Price - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Now Covered by Canaccord Genuity Group - Defense World
Interesting APGE Put And Call Options For December 2025 - Nasdaq
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):